Abstract: Major histocompatibility (B) complex (MHC) gene dose effects on Rous sarcoma outcome were examined using chickens aneuploid for the MHC-bearing chromosome. Six-week-old chickens were inoculated with subgroup A Rous sarcoma virus (RSV). Tumors were scored for size six times over a 10-wk period followed by assignment of a tumor profile index (TPI), which indicated the degree of tumor growth. In Experiment 1, matings between Line FCT-15 trisomic (B15B15B15) sires and dams produced disomic (B15B15), trisomic (B15B15B15), and tetrasomic (B15B15B15B15) progeny. The progressive tumor growth engendered by B15 did not differ significantly among the three B complex doses. In experiment 2, matings between UNH 193 (B19B19B19) trisomic parents produced progeny having 2, 3, and four B19 haplotype doses. Most Line 193 chickens regressed their tumors. However, disomic Line UNH 193 chickens had a significantly lower TPI than trisomic but not tetrasomic chickens. In experiment 3, Line UNH 193 was crossed with Line 6.15-5 (B5B5), a tumor progressor genotype, to produce either B5B19 or B5B19B19 genotypes. Mean tumor growth over time and mean TPI were significantly lower in B5B19B19 chickens compared with B5B19 chickens. These data indicate that B complex gene dose alterations for B15 did not affect Rous sarcomas but changes involving extra B19 doses enhanced tumor development. Furthermore, when combined with the progressive B5 haplotype, two doses of the tumor regressor-associated B19 haplotype were significantly more effective for inhibiting tumor development compared to one B19 dose.
Introduction
The chicken major histocompatibility (B) complex (MHC) resides on a single chromosome approximately 16th in size (Bloom and Bacon, 1985; Bloom et al., 1987) . This chromosome also contains a second group of genes, Rfp-Y, that has considerable MHC homology Miller et al., 1994 Miller et al., , 1996 . The nucleolar organizer region (NOR) encoding the ribosomal RNA genes, a region of high frequency recombination, separates the ( B) complex from Rfp-Y o n microchromosome 16. Line FCT-15 chickens that possess the B15 haplotype, are aneuploid (trisomic and tetrasomic) for the B complex-bearing chromosome and represent the only viable trisomic and tetrasomic animal model (Bloom and Bacon, 1985) . An important feature of this animal model is that B complex-encoded molecules are expressed in a dose-dependent manner, while ribosomal RNA gene expression is regulated i n aneuploid cells to diploid levels (Muscarella et al., 1985; Delany et al., 1988) . This unique model has been useful for studies of B complex dose effects on immune system development and functions as well as disease resistance. Previous research revealed expression of MHC antigens on B lymphocytes (Delany et al., 1988) increased proportionally with B complex gene dose. Bursal lymphocyte subpopulation profiles were also altered with B complex dose . Aneuploid MHC doses affected primary lymphoid organ development as well as bursal and thymic lymphocyte counts (Hemendinger et al., 1992) . In addition, class II MHC molecules on macrophages were expressed in proportion to their B complex chromosome dose (Qureshi et al., 1989; Lin et al., 1991 Lin et al., , 1993 . Macrophage functional analysis demonstrated that aneuploidy affected SRBC phagocytosis (Qureshi et al., 1989) , in vitro antigen presentation (Lin et al., 1991) , generation of reactive oxygen intermediates (Lin et al., 1992) , antitumor activity, and nitrite production (Lin et al., 1993) . Particular B complex genotypes exert a powerful influence on susceptibility to viral, bacterial, and parasitic disease vectors Kaufman et al., 1999) . Collins et al. (1977) and Schierman et al. (1977) first r eported the central role of the B complex i n determining tumor outcome after induction by the oncogenic retro virus, Rous sarcoma virus (RSV). Rous sarcomas in B2B2 and B5B5 chickens regressed and progressed, respectively (Collins et al., 1977) . Tumor regressed in B6B13 chickens but progressed in B13B13 chickens (Schierman et al., 1977) . Additional work by numerous investigators confirmed the MHC control of RSV tumor growth (Taylor, 2004 LePage et al., (1996) tumors, is one of a congenic pair described by Dix and examined the B complex gene dose effect on antibody . Progeny from this mating had either titers to the T cell-dependent antigen, sheep red blood B5B19 or B5B19B19 MHC chromosome doses. cells (SRBC) (B19B19B19) and Line 6.15-5 (B5B5) were pulp samples were prepared in 50% acetic acid and used to study the effects of B complex doses on RSVcoated on microscope slides as described previously induced tumors involving combinations of B19 tumor (Bloom and Bacon, 1985; Muscarella et al., 1985) . regressor and B5 tumor progressor B complex Nuclei were examined using phase contrast haplotypes.
examination according to the method of Delany et al.,
Materials and Methods
Stock: Animals utilized in Experiment 1 were the FCT-15 trisomic line ( B15B15B15) developed at Cornell University (Bloom and Bacon, 1985; Bloom et al., 1987) . These birds have three copies of the microchromosome, which bears both the major histocompatibility ( B) complex and the nucleolus organizer region (NOR). The number of NORs, and nucleoli they produce, serves as a useful diagnostic marker for the number of MHC-bearing chromosomes in cells. Matings between trisomic sires and dams produced disomic (B15B15), trisomic (B15B15B15), and tetrasomic (B15B15B15B15) progeny. Line UNH 193 trisomic chickens were derived from the FCT-15 trisomic line. A trisomic sire (B2B15B15) from a cross of FCT-15 trisomic line to inbred Line 6.6-2 (B2B2) (Miller et al., 1996) was mated to modified Wisconsin Line 3 Ancona dams (B19B19) to produce chickens having 3 B complex (B2B15B19) haplotypes. Trisomic dams were then back crossed twice to B19B19 Line 3 Ancona sires until trisomic chickens were homozygous for the B19B19B19 genotype. These chickens were the foundation for Line UNH 193. All blood types were confirmed by hemagglutination assays using alloantisera specific for B complex haplotypes (Briles and Briles, 1982) . Matings between Line UNH 193 trisomic sires and dams produced progeny having B19B19, B19B19B19 or B19B19B19B19 MHC haplotypes and these progeny were used i n (1992). The maximum number of nucleoli found in cells of each chicken indicates the number of MHC chromosome doses .
Virus Inoculations and Tumor Evaluation:
Six-week-old chickens were inoculated in the wing-web with 20 pock forming units (pfu) of RSV [subgroup A] in all three experiments. The tumors that developed were scored for size at 2, 3, 4, 6, 8, and 10 wk postinoculation using the values 0 = no palpable tumor; 1 = small tumor up to 0.5 cm diameter; 2 = tumor >0.5 up to 1.2 cm diameter; 3 = tumor >1.2 up to ½ wingweb area; 4 = tumor > ½ wingweb area, but <entire wingweb; 5 = tumor filling the entire wingweb; 6 = massive tumor extended beyond wingweb; and 7 = death during the experiment (Collins et al., 1977) . The six tumor size scores were used to assign a tumor profile index (TPI), which indicates the degree of tumor growth. The TPI values were 1 = complete regression by 28 days, or earlier; 2 = complete regression by 42 or 56 days; 3 = complete regression by 70 days, or a decreasing slope, or complete regression by 56 days followed by recurrence; 4 = general upward trend, or plateau or slight regression after 56 days; 5 = terminal tumor prior to 70 days (Collins et al., 1977) .
Statistical analysis:
Mean tumor sizes for each scoring period were evaluated by least squares analysis o f variance using a repeated measures split-plot design with hatch, sex and B complex gene dose as main effects in each experiment. The TPI values were rank transformed and analyzed by ANOVA as described by Conover and Iman (1981) . Fisher's Protected LSD at P <0.05 separated significant means. Tumor development and mortality were subjected to chi-square analysis.
Results
Tumors developed in 71 percent of the FCT-15 trisomic line progeny in Experiment 1. The tumor growth over time did not differ significantly (P > 0.05) as assessed by repeated measures ANOVA among 22 disomic (B15B15), 36 trisomic (B15B15B15), and 19 tetrasomic (B15B15B15B15) progeny (Fig. 1) . Tumors increased in size from 2 to 4 wk post-inoculation. Subsequent tumor growth reached a plateau in all three genotypes although tetrasomic chickens had a slight increase at 8 wk post-inoculation. The TPI of the three genotypes was statistically similar and sex was not significant. Mortality rates were 50.0, 36.1 and 52.6% for disomic, trisomic, and tetrasomic chickens, respectively. Less than 23% of any B complex gene dose completely regressed their tumors.
In Experiment 2, tumors developed in 70 percent of progeny from B19B19B19 x B19B19B19 matings. None of the gene doses differed significantly in the proportion of hosts that developed tumors. The mean TPI o f B19B19 chickens (n = 28) was significantly (P < 0.05) lower than the trisomic B19B19B19 TPI (n = 47). The TPI of B19B19B19B19 chickens (n = 13) did not differ significantly from either disomic or trisomic B complex gene doses. All three B complex gene doses had less than 18% mortality that did not differ significantly.
Complete tumor regression, also not significant, ranged from 78.6% in B19B19 in disomic chickens to 59.6% in B19B19B19 trisomics. Seventy percent of the disomic and trisomic progeny injected with RSV developed tumors in Experiment 3. The proportion of chickens that developed tumors did not differ between the two gene doses. The gene dose x time interaction was significant (P = 0.036) indicating that the two gene doses had different tumor growth over time (Fig. 3A) . The B5B19B19 genotype (n = 36) had lower tumor growth than the B5B19 genotype (n = 29). Fig. 3B shows that the TPI of B5B19B19 chickens was significantly (P = 0.015) lower than the TPI of B5B19 birds. There was no tumor growth or TPI difference between the sexes. Compared with the disomic dose, trisomic chickens had lower mortality (19.4% vs 41.3%) as well as a higher percentage of complete tumor regression (52.8% vs 31.0%).
Discussion
Line FCT-15 chickens did not demonstrate any difference in RSV-induced tumor growth. All three B complex doses (disomic, trisomic, tetrasomic) for MHC haplotype B15 had progressive tumor growth. This result is consistent with previous RSV tumor growth studies of progressive RSV subgroup B tumor growth compared with Line 63 (B2B2) (Bacon et al., 1983) . Greater tumor progression was also found in the B15B15 F progeny of 2 Line 15I (B15B15) x 6 (B2B2) inoculated with RSV 5 3 subgroups A, B and C compared with the B2B2 and B2B15 genotypes (Brown et al., 1984) . The B19 haplotype, that regressed tumors in the present studies was found in other previous work to be variably associated with tumor regression. For example, three homozygous genotypes from the Iowa State University Fig. 3 : Effect of major histocompatibility (B) complex S1 Leghorn line, were inoculated with RSV subgroup A.
gene dose on (A) tumor size scores over a 10-Tumor regression for chickens having B2B2, B19B19, wk experimental period and (B) tumor profile and B1B1 genotypes was 78, 44 and 21% respectively indices (TPI) in B5B19 (n = 29) and B5B19B19 (Gebriel et al., 1979) . In other studies, B19B19 chickens (n = 36) chicks inoculated with 20 pfu Rous had TPI that were significantly greater than either sarcoma virus. Tumor growth for the two B B21B21 or B21B19 chickens in a test of progeny genotypes differs significantly (P < 0.05) over segregating for B19 and B21 (Aeed et al., 1993) . The time. Bars having no common letter differ higher TPI indicated more tumor progression. significantly (P < 0.05). Tumor progression by the B5 haplotype is welldocumented. The F progeny of the inbred lines 6 cells (Taylor et al., 2004) . Thymic lymphocyte numbers al., 1992) . Tumor growth did not differ among the three in the B5B5 genotype (Collins et al., 1977) . Viral Line FCT-15 gene doses so the uniform progressive subgroup A or B tumors had progressive tumor growth outcome attributable to the B15 haplotype outweighed in B5B5 chickens from either inbred lines [6 (B2B2) x possible consequences of reduced lymphocytes. The 3 15 (B5B5)] F or Line 15I (Bacon et al., 1981 (Bacon et al., , 1983 . aneuploid effect was evident in Line UNH 193 because
The B5 antigen cross-reacted to one or more RSV tumor trisomic chickens had a higher TPI than did disomic antigens because Rous sarcoma progression chickens. increased in B2B2 chickens previously made tolerant to
The direct effect of MHC recognition and response the B5 antigen compared with untreated B2B2 controls influenced all three experiments. Experiments 1 and 2 (Heinzelmann et al., 1981a (Heinzelmann et al., , 1981b . Taylor et al. (1992;  employed different doses of homozygous MHC 1994) confirmed that the B2 haplotype controlled tumor haplotypes, B15 and B19. Therefore, MHC effects in regression whereas the B5 haplotype controlled tumor those homozgotes are based upon dosage rather than progression using MHC congenic lines.
the presence of dissimilar recognition capabilities. An RSV tumor growth is affected by an immune response indirect effect of altered MHC dose, such as lower thymic against antigens that are either encoded or induced by lymphocyte numbers, had more potential impact o n the virus (Taylor et al., 1992) . This immune response tumor outcome, particularly in the regressive type. This producing tumor regression is mediated primarily by T explanation seems plausible because in the Line UNH 193 B19 doses, trisomic and tetrasomics had higher tumor growth than did the disomics. MHC recognition in the B5 and B19 combinations likely had greater bearing on tumor growth than did an alteration of lymphocyte numbers. It is not know if an aneuploid condition lowered lymphocyte numbers when multiple MHC haplotypes were present. Trisomic chickens (B5B19B19) had significantly lower tumor growth and TPI compared with B5B19 disomic chickens. This result indicated that two regressive B19 doses overcame the B5 progressor type to a greater extent than did one B19 dose. Macrophage function has been evaluated in altered MHC gene doses. Phagocytic activity of unopsonized, but not opsonized SRBC was reduced in aneuploid birds (Qureshi et al., 1989) . Trisomic and tetrasomic Sephadex-elicited peritoneal macrophages had reduced antigen presentation (Lin et al., 1991) . In vitro anti-tumor activity and nitrite production (Lin et al., 1993) were lower in the aneuploid birds. Lower in vivo macrophage antitumor activity in trisomics might have contributed to the poorer response in Line UNH 193. Potential functional deficiencies in either T or B cells have received limited study. LePage et al. (1996) found anti-SRBC antibody did not differ among three B complex doses yet aneuploid chickens did have a more rapid decline from peak antibody titer compared to disomic chickens. Analysis of lymphocyte functions from trisomic and tetrasomic chickens is an area for future investigation. Aneuploidy for the MHC-bearing chromosome does not preclude the possibility that other genes on this chromosome may have affected the responses measured in the present study. For example, the Rfp-Y system contains MHC class I and MHC class II genes Miller et al., 1994) , maps to the same chromosome (Miller et al., 1996) but assorts independently of the B complex. Rous sarcoma outcome in B2B5 birds was affected by Rfp-Y genotype (LePage et al., 2000) . The Rfp-Y haplotypes in Line FCT-15 and UNH 193 are unknown and may impact tumor growth. Other studies (unpublished) suggest that extreme regressor or progressor genotypes such as B2B2 or B5B5 are not affected by Rfp-Y. Other non-MHC background genes not found on the aneuploid chromosome, such as erythrocyte or lymphocyte alloantigens (Medarova et al., 2003; Taylor 2004) , may have contributed to the differential tumor growth.
